Details
Stereochemistry | ACHIRAL |
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
[Ca++]
InChI
InChIKey=BHPQYMZQTOCNFJ-UHFFFAOYSA-N
InChI=1S/Ca/q+2
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlCurator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
Title | Date | PubMed |
---|---|---|
[Early stage of cardiomyopathy: mechanisms of damage and compensation]. | 1999 Jul |
|
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. | 1999 Sep |
|
C-reactive protein in the hemolymph of Achatina fulica: interrelationship with sex steroids and metallothionein. | 2000 Apr |
|
Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density. | 2000 Aug |
|
Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. | 2000 Dec |
|
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
Inactivation properties of human recombinant class E calcium channels. | 2000 Feb |
|
Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase. | 2000 Feb 1 |
|
Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V. | 2000 Feb 11 |
|
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties. | 2000 Jan 1 |
|
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation. | 2000 Jan 15 |
|
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. | 2000 Jan 7 |
|
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells. | 2000 Jun |
|
A family of gamma-like calcium channel subunits. | 2000 Mar 24 |
|
Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A. | 2000 May |
|
Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway. | 2000 May |
|
Ca2+-induced contraction of cat esophageal circular smooth muscle cells. | 2001 Apr |
|
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. | 2001 Apr 27 |
|
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. | 2001 Apr 7 |
|
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line. | 2001 Jul |
|
Analysis of the native quaternary structure of vanilloid receptor 1. | 2001 Jul 27 |
|
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D. | 2001 Jun |
|
[Acute renal failure caused by hypercalcemia]. | 2001 Jun 10 |
|
Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. | 2001 Mar |
|
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. | 2001 Mar 27 |
|
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism. | 2001 Nov |
|
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002 Feb 1 |
|
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. | 2002 Jan 15 |
|
Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002 Jun 15 |
|
Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002 Sep 15 |
|
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:44:14 GMT 2023
by
admin
on
Fri Dec 15 15:44:14 GMT 2023
|
Record UNII |
2M83C4R6ZB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
13959-2
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
53087-3
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
83064-6
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
WHO-ATC |
A12AA07
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
NCI_THESAURUS |
C68241
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
49936-8
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
53139-2
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
50837-4
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
59472-1
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
17863-2
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
12180-6
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
NDF-RT |
N0000184168
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
14415-4
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
WHO-ATC |
A12AA20
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
NCI_THESAURUS |
C597
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
41645-3
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
57333-7
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
17864-0
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
38230-9
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
34581-9
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
46093-1
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
41644-6
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
47596-2
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
49935-0
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
54367-8
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
53138-4
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
53140-0
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
59470-5
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
42567-8
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
54366-0
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
59471-3
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
53088-1
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
1994-3
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
47598-8
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
1995-0
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
59473-9
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
50838-2
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
41646-1
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
||
|
LOINC |
19072-8
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39123
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
N0000009252
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | Increased Coagulation Factor Activity [PE] | ||
|
2M83C4R6ZB
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
2M83C4R6ZB
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
39099
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
DTXSID7037638
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
SUB121174
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
29108
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
DB14577
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
100000144534
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
N0000166192
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | Cations, Divalent [Chemical/Ingredient] | ||
|
39124
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
C61660
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
1316581
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | RxNorm | ||
|
14127-61-8
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY | |||
|
271
Created by
admin on Fri Dec 15 15:44:15 GMT 2023 , Edited by admin on Fri Dec 15 15:44:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |